Review
Copyright ©The Author(s) 2023.
World J Gastrointest Surg. Apr 27, 2023; 15(4): 495-519
Published online Apr 27, 2023. doi: 10.4240/wjgs.v15.i4.495
Figure 1
Figure 1 Immunotherapeutic approaches against colorectal cancer. Antiangiogenic monoclonal antibodies like cetuximab, panitumumab, nimotuzumab, and necitumumab target epidermal growth factor (EGF) receptor (EGFR). Antiangiogenic monoclonal antibodies such as bevacizumab and ramucirumab target vascular EGF and its receptor, respectively. All antiangiogenic monoclonal antibodies downregulate the RAS-RAF-MEK-ERK pathway and prevent the transcription of genes involved in cell cycle progression. Immune checkpoint inhibitors (ICIs) like atezolizumab and avelumab target programmed cell death ligand 1 (PD-L1). ICIs like nivolumab, dostarlimab, and pembrolizumab target programmed cell death protein 1 (PD-1). The ICI ipilimumab targets cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). ICIs act as immune brakes that prevent checkpoint proteins from interacting with their companion proteins, thus boosting T cell effector activity. T cell boosting therapy, like adoptive cell therapy, includes chimeric antigen receptor T cell therapy (CAR-T), T cell receptor modification (TCR), and tumor infiltrating lymphocyte boost T cell activity to combat cancer cell growth. VEGF: Vascular epidermal growth factor; VEGFR: Vascular epidermal growth factor receptor.